Serina Therapeutics, Inc.·4

Feb 17, 8:24 AM ET

GILL SIMBA 4

Research Summary

AI-generated summary

Updated

Serina (SER) Director Gill Simba Receives 92,000-Share Option Award

What Happened

  • Director Gill Simba received a grant/award of 92,000 derivative shares (an option award) reported on Form 4 for the Feb 3, 2026 transaction. The filing lists an acquisition price of $0.00 and the transaction is coded as an award/other acquisition (A).
  • The grant shows $0 cash paid at grant (typical for option awards); the filing excerpt does not list an exercise price or a market value realized, so no immediate cash value is reported.

Key Details

  • Transaction date: 2026-02-03; Form 4 filed: 2026-02-17.
  • Reported acquisition price: $0.00; Total reported cash exchanged at grant: $0.
  • Shares owned after transaction: not specified in the provided excerpt.
  • Footnote: Vesting schedule — 12/48ths of the option vests 12 months after the Vesting Commencement Date, then 1/48th vests each month thereafter until fully vested (a typical 4‑year schedule with a 1‑year cliff).
  • Timeliness: The Form 4 was filed 14 days after the transaction date; Form 4s are normally due within 2 business days, so this appears delayed based on the provided dates.

Context

  • This is a compensation-related option award to a director, not an open-market purchase or sale. Such grants are common for directors and do not by themselves indicate trading intent.
  • Because the award vests over time, the shares are not immediately available for sale; the footnote shows a standard vesting ramp. No cashless exercise or immediate sale was reported.